ID

34886

Description

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT02395601

Link

https://clinicaltrials.gov/show/NCT02395601

Keywords

Versions (1)
  1. 2/2/19 2/2/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 2, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility B-Cell Lymphoma NCT02395601

English

Eligibility B-Cell Lymphoma NCT02395601

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
adults (aged ≥ 18 years)
Description

Adult | Age

Data type

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
histologically confirmed diagnosis of a b-cell lymphoma that has progressed in spite of prior treatment, and for which additional effective standard therapy is not available
Description

B-Cell Lymphoma | Prior Therapy | Disease Progression | Standard therapy Effective Lacking

Data type

boolean

Alias
UMLS CUI [1]
C0079731
UMLS CUI [2]
C1514463
UMLS CUI [3]
C0242656
UMLS CUI [4,1]
C2936643
UMLS CUI [4,2]
C1280519
UMLS CUI [4,3]
C0332268
eastern cooperative oncology group (ecog) performance status ≤ 2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
adequate hematological, renal, hepatic, and coagulation laboratory assessments
Description

Laboratory Procedures Hematologic function | Laboratory Procedures Renal function | Laboratory Procedures Liver function | Laboratory Procedures Blood coagulation

Data type

boolean

Alias
UMLS CUI [1,1]
C0022885
UMLS CUI [1,2]
C0221130
UMLS CUI [2,1]
C0022885
UMLS CUI [2,2]
C0232804
UMLS CUI [3,1]
C0022885
UMLS CUI [3,2]
C0232741
UMLS CUI [4,1]
C0022885
UMLS CUI [4,2]
C0005778
must give written informed consent to participate in this study before the performance of any study-related procedure
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
a primary lymphoma of the central nervous system (cns) or known lymphomatous involvement of the cns
Description

Primary central nervous system lymphoma | Central Nervous System Involvement Lymphomatous

Data type

boolean

Alias
UMLS CUI [1]
C0280803
UMLS CUI [2,1]
C4050309
UMLS CUI [2,2]
C0024299
impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of cpi-1205, including any unresolved nausea, vomiting, or diarrhea that is ctcae grade >1
Description

Impaired gastrointestinal system function Changing Absorption CPI-1205 | Gastrointestinal Disease Changing Absorption CPI-1205 | Nausea CTCAE Grades | Vomiting CTCAE Grades | Diarrhea CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0232459
UMLS CUI [1,2]
C0392747
UMLS CUI [1,3]
C0237442
UMLS CUI [1,4]
C4053654
UMLS CUI [2,1]
C0017178
UMLS CUI [2,2]
C0392747
UMLS CUI [2,3]
C0237442
UMLS CUI [2,4]
C4053654
UMLS CUI [3,1]
C0027497
UMLS CUI [3,2]
C1516728
UMLS CUI [4,1]
C0042963
UMLS CUI [4,2]
C1516728
UMLS CUI [5,1]
C0011991
UMLS CUI [5,2]
C1516728
treatment with proton pump inhibitors, h2 antagonists, or antacids
Description

Proton Pump Inhibitors | H2 Antagonists | Antacids

Data type

boolean

Alias
UMLS CUI [1]
C0358591
UMLS CUI [2]
C0019593
UMLS CUI [3]
C0003138
achlorhydria, either documented or suspected on the basis of an associated disease (e.g., pernicious anemia, atrophic gastritis, or certain gastric surgical procedures)
Description

Achlorhydria | Achlorhydria Suspected Due to Comorbidity | Anemia, Pernicious | Gastritis, Atrophic | Operation on stomach

Data type

boolean

Alias
UMLS CUI [1]
C0001075
UMLS CUI [2,1]
C0001075
UMLS CUI [2,2]
C0750491
UMLS CUI [2,3]
C0678226
UMLS CUI [2,4]
C0009488
UMLS CUI [3]
C0002892
UMLS CUI [4]
C0017154
UMLS CUI [5]
C0192398
impaired cardiac function or clinically significant cardiac diseases, including any of the following:
Description

Decreased cardiac function | Heart Diseases Clinical Significance

Data type

boolean

Alias
UMLS CUI [1]
C0232166
UMLS CUI [2,1]
C0018799
UMLS CUI [2,2]
C2826293
acute myocardial infarction or angina pectoris ≤ 6 months prior to starting study drug
Description

Myocardial Infarction | Angina Pectoris

Data type

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2]
C0002962
new york heart association class iii or iv congestive heart failure
Description

Congestive heart failure New York Heart Association Classification

Data type

boolean

Alias
UMLS CUI [1,1]
C0018802
UMLS CUI [1,2]
C1275491
qtcf > 470 msec on the screening ecg
Description

QTcF Prolongation ECG

Data type

boolean

Alias
UMLS CUI [1,1]
C3828431
UMLS CUI [1,2]
C0013798
uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded)
Description

Cardiac Arrhythmia Uncontrolled | ATRIAL FIBRILLATION VENTRICULAR RATE CONTROLLED allowed

Data type

boolean

Alias
UMLS CUI [1,1]
C0003811
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0741286
UMLS CUI [2,2]
C0683607
a past medical history of other clinically significant cardiovascular disease (e.g., uncontrolled hypertension, history of labile hypertension or history of poor compliance with an antihypertensive regimen)
Description

Cardiovascular Disease Medical History | Uncontrolled hypertension | Labile hypertension | Antihypertensive therapy Poor compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0262926
UMLS CUI [2]
C1868885
UMLS CUI [3]
C3665418
UMLS CUI [4,1]
C0585941
UMLS CUI [4,2]
C0032646
any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study (e.g., clinically significant pulmonary disease, clinically significant neurological disorder, active or uncontrolled infection)
Description

Comorbidity Severe compromises Study Subject Participation Status | Comorbidity Uncontrolled compromises Study Subject Participation Status | Lung diseases | Nervous system disorder | Communicable Disease | Communicable Disease Uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C2945640
UMLS CUI [1,4]
C2348568
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C0205318
UMLS CUI [2,3]
C2945640
UMLS CUI [2,4]
C2348568
UMLS CUI [3]
C0024115
UMLS CUI [4]
C0027765
UMLS CUI [5]
C0009450
UMLS CUI [6,1]
C0009450
UMLS CUI [6,2]
C0205318
systemic anti-cancer treatment or radiotherapy less than 2 weeks before the first dose of cpi 1205
Description

Cancer treatment Systemic | Therapeutic radiology procedure Systemic | Status pre- CPI-1205 Dose

Data type

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205373
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0205373
UMLS CUI [3,1]
C0332152
UMLS CUI [3,2]
C4053654
UMLS CUI [3,3]
C0178602
radioimmunotherapy (e.g., 131i-tositumomab, 90y-ibritumomab tiuxetan) less than 6 weeks before the first dose of cpi-1205
Description

Radioimmunotherapy | iodine-131-tositumomab | yttrium-90-ibritumomab tiuxetan | Status pre- CPI-1205 Dose

Data type

boolean

Alias
UMLS CUI [1]
C0085101
UMLS CUI [2]
C0768182
UMLS CUI [3]
C1134535
UMLS CUI [4,1]
C0332152
UMLS CUI [4,2]
C4053654
UMLS CUI [4,3]
C0178602
treatment with an investigational small molecule less than 2 weeks before the first dose of cpi-1205.
Description

Small Molecule Investigational | Status pre- CPI-1205 Dose

Data type

boolean

Alias
UMLS CUI [1,1]
C1328819
UMLS CUI [1,2]
C1517586
UMLS CUI [2,1]
C0332152
UMLS CUI [2,2]
C4053654
UMLS CUI [2,3]
C0178602
treatment with a therapeutic antibody less than 4 weeks before the first dose of cpi-1205.
Description

Antibody therapy | Status pre- CPI-1205 Dose

Data type

boolean

Alias
UMLS CUI [1]
C0281176
UMLS CUI [2,1]
C0332152
UMLS CUI [2,2]
C4053654
UMLS CUI [2,3]
C0178602
treatment with medications that are strong inhibitors of cyp3a4
Description

CYP3A4 Inhibitor

Data type

boolean

Alias
UMLS CUI [1]
C3830624
treatment with medications that are inducers of cyp3a4 enzymes
Description

CYP3A4 Inducer

Data type

boolean

Alias
UMLS CUI [1]
C3830625
treatment with medications that are known to carry a risk of torsades de pointes
Description

Pharmaceutical Preparations At risk Torsades de Pointes

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C0040479
pregnant or lactating women
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
women of child bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafter
Description

Females & males of reproductive potential Contraceptive methods Unwilling

Data type

boolean

Alias
UMLS CUI [1,1]
C4034483
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C0558080
patients unwilling or unable to comply with this study protocol
Description

Protocol Compliance Unwilling | Protocol Compliance Unable

Data type

boolean

Alias
UMLS CUI [1,1]
C0525058
UMLS CUI [1,2]
C0558080
UMLS CUI [2,1]
C0525058
UMLS CUI [2,2]
C1299582
Back to the top of the page

Similar models

Eligibility B-Cell Lymphoma NCT02395601

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adults (aged ≥ 18 years)
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
B-Cell Lymphoma | Prior Therapy | Disease Progression | Standard therapy Effective Lacking
Item
histologically confirmed diagnosis of a b-cell lymphoma that has progressed in spite of prior treatment, and for which additional effective standard therapy is not available
boolean
C0079731 (UMLS CUI [1])
C1514463 (UMLS CUI [2])
C0242656 (UMLS CUI [3])
C2936643 (UMLS CUI [4,1])
C1280519 (UMLS CUI [4,2])
C0332268 (UMLS CUI [4,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status ≤ 2
boolean
C1520224 (UMLS CUI [1])
Laboratory Procedures Hematologic function | Laboratory Procedures Renal function | Laboratory Procedures Liver function | Laboratory Procedures Blood coagulation
Item
adequate hematological, renal, hepatic, and coagulation laboratory assessments
boolean
C0022885 (UMLS CUI [1,1])
C0221130 (UMLS CUI [1,2])
C0022885 (UMLS CUI [2,1])
C0232804 (UMLS CUI [2,2])
C0022885 (UMLS CUI [3,1])
C0232741 (UMLS CUI [3,2])
C0022885 (UMLS CUI [4,1])
C0005778 (UMLS CUI [4,2])
Informed Consent
Item
must give written informed consent to participate in this study before the performance of any study-related procedure
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Primary central nervous system lymphoma | Central Nervous System Involvement Lymphomatous
Item
a primary lymphoma of the central nervous system (cns) or known lymphomatous involvement of the cns
boolean
C0280803 (UMLS CUI [1])
C4050309 (UMLS CUI [2,1])
C0024299 (UMLS CUI [2,2])
Impaired gastrointestinal system function Changing Absorption CPI-1205 | Gastrointestinal Disease Changing Absorption CPI-1205 | Nausea CTCAE Grades | Vomiting CTCAE Grades | Diarrhea CTCAE Grades
Item
impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of cpi-1205, including any unresolved nausea, vomiting, or diarrhea that is ctcae grade >1
boolean
C0232459 (UMLS CUI [1,1])
C0392747 (UMLS CUI [1,2])
C0237442 (UMLS CUI [1,3])
C4053654 (UMLS CUI [1,4])
C0017178 (UMLS CUI [2,1])
C0392747 (UMLS CUI [2,2])
C0237442 (UMLS CUI [2,3])
C4053654 (UMLS CUI [2,4])
C0027497 (UMLS CUI [3,1])
C1516728 (UMLS CUI [3,2])
C0042963 (UMLS CUI [4,1])
C1516728 (UMLS CUI [4,2])
C0011991 (UMLS CUI [5,1])
C1516728 (UMLS CUI [5,2])
Proton Pump Inhibitors | H2 Antagonists | Antacids
Item
treatment with proton pump inhibitors, h2 antagonists, or antacids
boolean
C0358591 (UMLS CUI [1])
C0019593 (UMLS CUI [2])
C0003138 (UMLS CUI [3])
Achlorhydria | Achlorhydria Suspected Due to Comorbidity | Anemia, Pernicious | Gastritis, Atrophic | Operation on stomach
Item
achlorhydria, either documented or suspected on the basis of an associated disease (e.g., pernicious anemia, atrophic gastritis, or certain gastric surgical procedures)
boolean
C0001075 (UMLS CUI [1])
C0001075 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0678226 (UMLS CUI [2,3])
C0009488 (UMLS CUI [2,4])
C0002892 (UMLS CUI [3])
C0017154 (UMLS CUI [4])
C0192398 (UMLS CUI [5])
Decreased cardiac function | Heart Diseases Clinical Significance
Item
impaired cardiac function or clinically significant cardiac diseases, including any of the following:
boolean
C0232166 (UMLS CUI [1])
C0018799 (UMLS CUI [2,1])
C2826293 (UMLS CUI [2,2])
Myocardial Infarction | Angina Pectoris
Item
acute myocardial infarction or angina pectoris ≤ 6 months prior to starting study drug
boolean
C0027051 (UMLS CUI [1])
C0002962 (UMLS CUI [2])
Congestive heart failure New York Heart Association Classification
Item
new york heart association class iii or iv congestive heart failure
boolean
C0018802 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
QTcF Prolongation ECG
Item
qtcf > 470 msec on the screening ecg
boolean
C3828431 (UMLS CUI [1,1])
C0013798 (UMLS CUI [1,2])
Cardiac Arrhythmia Uncontrolled | ATRIAL FIBRILLATION VENTRICULAR RATE CONTROLLED allowed
Item
uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded)
boolean
C0003811 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0741286 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
Cardiovascular Disease Medical History | Uncontrolled hypertension | Labile hypertension | Antihypertensive therapy Poor compliance
Item
a past medical history of other clinically significant cardiovascular disease (e.g., uncontrolled hypertension, history of labile hypertension or history of poor compliance with an antihypertensive regimen)
boolean
C0007222 (UMLS CUI [1,1])
C0262926 (UMLS CUI [1,2])
C1868885 (UMLS CUI [2])
C3665418 (UMLS CUI [3])
C0585941 (UMLS CUI [4,1])
C0032646 (UMLS CUI [4,2])
Comorbidity Severe compromises Study Subject Participation Status | Comorbidity Uncontrolled compromises Study Subject Participation Status | Lung diseases | Nervous system disorder | Communicable Disease | Communicable Disease Uncontrolled
Item
any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study (e.g., clinically significant pulmonary disease, clinically significant neurological disorder, active or uncontrolled infection)
boolean
C0009488 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C2945640 (UMLS CUI [1,3])
C2348568 (UMLS CUI [1,4])
C0009488 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C2945640 (UMLS CUI [2,3])
C2348568 (UMLS CUI [2,4])
C0024115 (UMLS CUI [3])
C0027765 (UMLS CUI [4])
C0009450 (UMLS CUI [5])
C0009450 (UMLS CUI [6,1])
C0205318 (UMLS CUI [6,2])
Cancer treatment Systemic | Therapeutic radiology procedure Systemic | Status pre- CPI-1205 Dose
Item
systemic anti-cancer treatment or radiotherapy less than 2 weeks before the first dose of cpi 1205
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0205373 (UMLS CUI [2,2])
C0332152 (UMLS CUI [3,1])
C4053654 (UMLS CUI [3,2])
C0178602 (UMLS CUI [3,3])
Radioimmunotherapy | iodine-131-tositumomab | yttrium-90-ibritumomab tiuxetan | Status pre- CPI-1205 Dose
Item
radioimmunotherapy (e.g., 131i-tositumomab, 90y-ibritumomab tiuxetan) less than 6 weeks before the first dose of cpi-1205
boolean
C0085101 (UMLS CUI [1])
C0768182 (UMLS CUI [2])
C1134535 (UMLS CUI [3])
C0332152 (UMLS CUI [4,1])
C4053654 (UMLS CUI [4,2])
C0178602 (UMLS CUI [4,3])
Small Molecule Investigational | Status pre- CPI-1205 Dose
Item
treatment with an investigational small molecule less than 2 weeks before the first dose of cpi-1205.
boolean
C1328819 (UMLS CUI [1,1])
C1517586 (UMLS CUI [1,2])
C0332152 (UMLS CUI [2,1])
C4053654 (UMLS CUI [2,2])
C0178602 (UMLS CUI [2,3])
Antibody therapy | Status pre- CPI-1205 Dose
Item
treatment with a therapeutic antibody less than 4 weeks before the first dose of cpi-1205.
boolean
C0281176 (UMLS CUI [1])
C0332152 (UMLS CUI [2,1])
C4053654 (UMLS CUI [2,2])
C0178602 (UMLS CUI [2,3])
CYP3A4 Inhibitor
Item
treatment with medications that are strong inhibitors of cyp3a4
boolean
C3830624 (UMLS CUI [1])
CYP3A4 Inducer
Item
treatment with medications that are inducers of cyp3a4 enzymes
boolean
C3830625 (UMLS CUI [1])
Pharmaceutical Preparations At risk Torsades de Pointes
Item
treatment with medications that are known to carry a risk of torsades de pointes
boolean
C0013227 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0040479 (UMLS CUI [1,3])
Pregnancy | Breast Feeding
Item
pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Females & males of reproductive potential Contraceptive methods Unwilling
Item
women of child bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafter
boolean
C4034483 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
Protocol Compliance Unwilling | Protocol Compliance Unable
Item
patients unwilling or unable to comply with this study protocol
boolean
C0525058 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2,1])
C1299582 (UMLS CUI [2,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial